Trinity is delighted to be working again with Contura International Ltd, (manufacturers of therapeutic hydrogels) to support the official launch of Arthrosamid® to the UK market. The brand’s presence was first ‘unveiled’ at the recent British Orthopaedic Association (BOA) Annual Congress last month (held in Aberdeen from 21st-24th September). Published data (from a study in Osteoarthritis and Cartilage, 2021) showed that 70% of patients had a positive experience of treatment with Arthrosamid®, with a reduction in pain and stiffness, as well as improved physical mobility after a year1.
Arthrosamid® – a novel injectable treatment for knee osteoarthritis that harnesses non-biodegradable hydrogel technology – offers an alternative to current surgical and drug therapies and fulfils an unmet clinical need for an effective, long acting, safe and minimally invasive treatment to alleviate pain associated with knee osteoarthritis (OA).
The treatment has the potential to change the present care pathway for managing OA, which effects approximately 8.5 million people in the UK2. Around 1 in every 5 people aged over 45 in England is affected by knee osteoarthritis3 and current treatments are not long lasting or involve invasive knee replacement surgery. Despite a large suffering population, there has been very little innovation in the range of OA treatments on offer to meaningfully help patients – until now.
During the BOA Congress, Contura International Ltd, also hosted a thought leadership session to present the clinical data supporting Arthrosamid® to delegates and to discuss this new non-degradable viscoelastic hydrogel for adults with knee OA.
And, new consumer insight commissioned as part of the new campaign, also found that 44% of people rank joint & knee pain as their top concern about ‘getting older’, while only half of that amount (22%) are worried about the visible effects of ageing, such as wrinkles. Overall, people say they’d put up with knee pain for nearly 4 months (15 weeks) before seeking advice from their GP. And interestingly, over two thirds (68%) of people said they would be concerned about using painkillers on a long-term basis to help manage chronic pain
Rakesh Tailor, Chief Operating Officer at Contura International Ltd comments, “After 10 years of rigorous testing, biocompatibility analyses and clinical studies, and two decades after the idea to investigate the use of hydrogel in human joints was first suggested, we’re delighted that Arthrosamid® is now available as a treatment for pain associated with knee OA. The discomfort caused by OA can significantly impact a patient’s quality of life and make everyday activities challenging. For patients under 70 who are deemed too young for knee replacement surgery, Arthrosamid® particularly represents a game changing treatment option where just one injection provides long lasting pain relief and mobility without the need for surgery. We are excited to work with experts to establish what is potentially a new treatment algorithm for patients suffering with knee OA.”
References: 1. Bliddal H, Overgaard A, Hartkopp A, Beier J, Conaghan PG, et al. (2021) Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results of a 52 Week Prospective Study. Osteoarthritis and CartilageVol. 29 S278: 2021. 2. https://www.nice.org.uk/guidance/cg177/documents/osteoarthritis-update-final-scope2 3. birmingham-oa-1.pdf (versusarthritis.org)
Treatment with Arthrosamid® is simple. The knee is prepared by cleaning the area around the injection site.
The knee is numbed with some local anaesthetic, before aspirating if necessary.
Using ultrasound guidance, Arthrosamid® is injected into the knee.